Russia’s COVID-19 vaccine showed antibody response in early trials: The Lancet

Russia's COVID-19 vaccine showed antibody response in early trials: The Lancet

Russia’s ‘Sputnik V’ COVID-19 vaccine produced an antibody response in all participants, according to results published by The Lancet medical journal.

The results of the two trials showed 100% of participants developing antibodies to the new coronavirus and no serious side effects, The Lancet said.

“The two 42-day trials – including 38 healthy adults each – did not find any serious adverse effects among participants, and confirmed that the vaccine candidates elicit an antibody response,” The Lancet said.

“Large, long-term trials including a placebo comparison, and further monitoring are needed to establish the long-term safety and effectiveness of the vaccine for preventing COVID-19 infection,” it said.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

multimedia

news